<p> Top executives of American pharma companies favour “dialogue” with India and “not confrontation” to address their concerns on key issues like the protection of intellectual property (IP) and clinical trials.<br /><br /></p>.<p>Arguing that global pharma companies share the same goal of “patient first” with that of the Government of India, corporate executives attending the day-long “US-India BioPharma and Healthcare Summit” organised by the USA-India Chamber of Commerce said they should not be considered as adversaries by New Delhi.<br /><br />While asserting there can be no compromise on IP protection issues, executives from top US pharma companies said that they are willing to work with India like – tier pricing – to come out with a solution, which is acceptable to the both the parties.<br /><br />“We can sit around a table and have a dialogue. We need to move from seeing the industry as adversary to work together to help patients. The only way we can do it is by having collaboration and actually a dialogue,” Bahija Jallal, executive Vice President of MedImmune, a prominent bio-tech company, said.<br /><br />“We want to work together with the Indian Government.<br /><br />But we can't right now, go (to India) in a meaningful way if there is no IP protection,” she Jallal adding that New Delhi's compulsory licensing policies would force pharma companies to go to some other countries.<br /><br /> “The Government has to understand, the first thing that we care about is the patient. We can have a dialogue. Every country that we go to, we understand the different layers that exists economically,” she said.<br /><br />Dr Robert Langer, David J Koch Institute Professor at the prestigious Massachusetts Institute of Technology (MIT), argued that not protecting intellectual property would destroy innovation in the long term.</p>
<p> Top executives of American pharma companies favour “dialogue” with India and “not confrontation” to address their concerns on key issues like the protection of intellectual property (IP) and clinical trials.<br /><br /></p>.<p>Arguing that global pharma companies share the same goal of “patient first” with that of the Government of India, corporate executives attending the day-long “US-India BioPharma and Healthcare Summit” organised by the USA-India Chamber of Commerce said they should not be considered as adversaries by New Delhi.<br /><br />While asserting there can be no compromise on IP protection issues, executives from top US pharma companies said that they are willing to work with India like – tier pricing – to come out with a solution, which is acceptable to the both the parties.<br /><br />“We can sit around a table and have a dialogue. We need to move from seeing the industry as adversary to work together to help patients. The only way we can do it is by having collaboration and actually a dialogue,” Bahija Jallal, executive Vice President of MedImmune, a prominent bio-tech company, said.<br /><br />“We want to work together with the Indian Government.<br /><br />But we can't right now, go (to India) in a meaningful way if there is no IP protection,” she Jallal adding that New Delhi's compulsory licensing policies would force pharma companies to go to some other countries.<br /><br /> “The Government has to understand, the first thing that we care about is the patient. We can have a dialogue. Every country that we go to, we understand the different layers that exists economically,” she said.<br /><br />Dr Robert Langer, David J Koch Institute Professor at the prestigious Massachusetts Institute of Technology (MIT), argued that not protecting intellectual property would destroy innovation in the long term.</p>